According to Tang, this independence suggests that each biomarker provides unique prognostic information, making both valuable for understanding patient outcomes. Building on these findings, the ...

Time to first symptomatic skeletal event, whether including or excluding death, was similar between treatment arms. Most patients did not experience skeletal complications during the follow-up period.

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...

At the 2026 ASCO Genitourinary Cancers Symposium, Dr. Andrea Necchi shared the final results of the SunRISe-2 phase 3 trial, ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines. Patients with relapsed/refractory ...

“Incorporating ctDNA into the decision-making process helps refine who can safely keep their bladder,” Ghatalia, associate professor, Department of Hematology/Oncology, at Fox Chase Cancer Center in ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 ...